Safety and effectiveness of dulaglutide 0.75 mg in Japanese patients with type 2 diabetes in real‐world clinical practice: 36 month post‐marketing observational study

Safety and effectiveness of dulaglutide 0.75 mg in Japanese patients with type 2 diabetes in real‐world clinical practice: 36 month post‐marketing observational study

ABSTRACT Aims/Introduction This study evaluated the safety and effectiveness of dulaglutide in patients with type 2 diabetes in the real‐world setting in Japan. Materials and Methods This prospective, observational post‐marketing surveillance study was conducted for 36 months (July 2016 to July 2021...

Full description

Bibliographic Details
Main Authors:	Rina Chin, Soshi Nagaoka, Haru Nakasawa, Yoko Tanaka, Nobuya Inagaki
Format:	Article
Language:	English
Published:	Wiley 2023-02-01
Series:	Journal of Diabetes Investigation
Subjects:	Diabetes type 2 Dulaglutide Glucagon‐like peptide‐1 receptor
Online Access:	https://doi.org/10.1111/jdi.13932

Similar Items

Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND
by: Manige Konig, et al.
Published: (2021-09-01)

Weight-dependent and weight-independent effects of dulaglutide on blood pressure in patients with type 2 diabetes
by: Keith C. Ferdinand, et al.
Published: (2023-03-01)

Evaluation of the impact of once weekly dulaglutide on patient-reported outcomes in Japanese patients with type 2 diabetes: comparisons with liraglutide, insulin glargine, and placebo in two randomized studies
by: Shuichi Suzuki, et al.
Published: (2017-06-01)

Once-weekly administration of dulaglutide, a glucagon-like peptide-1 receptor agonist, as monotherapy and combination therapy: review of the AWARD studies
by: Marina V. Shestakova, et al.
Published: (2017-08-01)

Assessment of Changes in Body Composition After 3 Months of Dulaglutide Treatment
by: Chen S, et al.
Published: (2024-03-01)

Dulaglutide as an Add-on to Insulin in Type 2 Diabetes; Clinical Efficacy and Parameters Affecting the Response in Real-World Practice
by: Lee J, et al.
Published: (2019-12-01)

Assessment of Changes in Body Composition After 3 Months of Dulaglutide Treatment [Letter]
by: Panjaitan NSD, et al.
Published: (2024-04-01)

Efficacy of dulaglutide on vascular health indexes in subjects with type 2 diabetes: a randomized trial
by: Antonino Tuttolomondo, et al.
Published: (2021-01-01)

The use of the GLP-1 analog - dulaglutide in the treatment of morbid obesity - case report
by: Agata Juda, et al.
Published: (2022-11-01)

Exacerbation of atrial fibrillation related to dulaglutide use
by: Jayden Lee, et al.
Published: (2021-05-01)

Effects of switching from liraglutide to semaglutide or dulaglutide in patients with type 2 diabetes: A randomized controlled trial
by: Takahiro Iijima, et al.
Published: (2023-06-01)

Advances in the treatment of type 2 diabetes: impact of dulaglutide
by: Thompson AM, et al.
Published: (2016-05-01)

Efficacy and safety of dulaglutide: a novel once-weekly glucagon-like peptide-1 analogue
by: A. S. Pogorelova, et al.
Published: (2018-03-01)

Mode of administration of dulaglutide: implications for treatment adherence
by: Amblee A
Published: (2016-06-01)

An exploratory clinical trial on the efficacy and safety of glucagon-like peptide-1 receptor agonist dulaglutide in patients with type 2 diabetes on maintenance hemodialysis
by: Daisuke Ugamura, et al.
Published: (2022-06-01)

Economic Evaluation of Dulaglutide vs Traditional Therapies: Implications of the Outcomes of the Rewind Study
by: Torre E, et al.
Published: (2020-04-01)

Hypersensitivity to glucagon‐like peptide‐1 receptor agonists: A case of delayed urticaria‐like rash to dulaglutide and literature review
by: Leonardo Bianchi, et al.
Published: (2024-03-01)

Effects of dulaglutide on endothelial progenitor cells and arterial elasticity in patients with type 2 diabetes mellitus
by: Dandan Xie, et al.
Published: (2022-10-01)

Improvement of Left Ventricular Global Longitudinal Strain after 6-Month Therapy with GLP-1RAs Semaglutide and Dulaglutide in Type 2 Diabetes Mellitus: A Pilot Study
by: Paolo Basile, et al.
Published: (2023-02-01)

Efficacy and safety of dulaglutide in patients with absolute insulin deficiency
by: Kutoh Eiji, et al.
Published: (2019-07-01)

Dulaglutide as an Effective Replacement for Prandial Insulin in Kidney Transplant Recipients with Type 2 Diabetes Mellitus: A Retrospective Review
by: Hwi Seung Kim, et al.
Published: (2021-11-01)

Dulaglutide improves glucocorticoid-induced hyperglycemia in inpatient care and reduces dose and injection frequency of insulin
by: Hiroyuki Uchinuma, et al.
Published: (2020-05-01)

Remitting Seronegative Symmetrical Synovitis with Pitting Edema Syndrome Worsen after the Administration of Dulaglutide
by: Toshitaka Sawamura, et al.
Published: (2022-02-01)

Effect of dulaglutide injection on weight beyond glycemic control: Real-world observational study
by: Adel G. Mohammed, et al.
Published: (2023-02-01)

Comparative effectiveness of dulaglutide versus liraglutide in Asian type 2 diabetes patients: a multi-institutional cohort study and meta-analysis
by: Kai-Cheng Chang, et al.
Published: (2020-10-01)

Effects of once-weekly dulaglutide on juvenile type 2 diabetes mellitus and obesity in Korea: a pilot study
by: Ji Young Seo, et al.
Published: (2023-02-01)

Dulaglutide Ameliorates Palmitic Acid-Induced Hepatic Steatosis by Activating FAM3A Signaling Pathway
by: Jinmi Lee, et al.
Published: (2022-02-01)

Effects of a Dulaglutide plus Calorie-Restricted Diet versus a Calorie-Restricted Diet on Visceral Fat and Metabolic Profiles in Women with Polycystic Ovary Syndrome: A Randomized Controlled Trial
by: Yuqin Zhang, et al.
Published: (2023-01-01)

Real-World Efficacy of Glucagon-like Peptide-1 (GLP-1) Receptor Agonist, Dulaglutide, on Metabolic Parameters in Japanese Patients with Type 2 Diabetes: A Retrospective Longitudinal Study
by: Hisayuki Katsuyama, et al.
Published: (2023-03-01)

The renoprotective effect of once‐weekly GLP‐1 receptor agonist dulaglutide on progression of nephropathy in Japanese patients with type 2 diabetes and moderate to severe chronic kidney disease (JDDM67)
by: Ken‐ichi Tsuchida, et al.
Published: (2022-11-01)

Dulaglutide treatment reverses depression‐like behavior and hippocampal metabolomic homeostasis in mice exposed to chronic mild stress
by: Man Jin, et al.
Published: (2024-03-01)

The short-term cost-effectiveness of once-weekly semaglutide versus once-weekly dulaglutide for the treatment of type 2 diabetes mellitus in Colombian adults [version 2; peer review: 2 approved]
by: Sharon Lechtig-Wassermann, et al.
Published: (2023-12-01)

An observational study evaluating effectiveness and therapeutic adherence in patients with Type 2 Diabetes initiating dulaglutide vs. subcutaneous semaglutide in Spain
by: Santiago Tofé, et al.
Published: (2021-03-01)

Once weekly dulaglutide therapy in type 2 diabetic subjects, real-world evidence from a tertiary care diabetes center in India
by: Jasjeet S Wasir, et al.
Published: (2018-01-01)

Bullous pemphigoid triggered by dulaglutide: a case report and a review of the literature
by: Benedetta Sonego, et al.
Published: (2023-06-01)

Achieving the composite end‐point of glycated hemoglobin <7.0% without weight gain or hypoglycemia with once‐weekly dulaglutide in Chinese patients with type 2 diabetes: A post‐hoc analysis
by: Xinhua Xiao, et al.
Published: (2020-05-01)

Efficacy of dulaglutide: an evidence-based review of its potential indications
by: E. V. Biryukova, et al.
Published: (2021-05-01)

Effects of dulaglutide combined with insulin degludec on glucose fluctuations and appetite in type 2 diabetes
by: Jinxin Huang, et al.
Published: (2023-05-01)

Long‐Term Activation of Glucagon‐like peptide‐1 receptor by Dulaglutide Prevents Diabetic Heart Failure and Metabolic Remodeling in Type 2 Diabetes
by: Saiyang Xie, et al.
Published: (2022-10-01)

Pharmacoeconomic analysis (CER) of Dulaglutide and Liraglutide in the treatment of patients with type 2 diabetes
by: Yu Su, et al.
Published: (2023-01-01)